Candel Therapeutics Reports Durable Immune Activation in Prostate Cancer Trial
Event summary
- Candel Therapeutics reported durable local and systemic immune activation in intermediate-risk localized prostate cancer patients treated with aglatimagene besadenovec.
- Phase 3 trial data showed a 41% reduction in the risk of prostate cancer recurrence or death versus placebo plus EBRT (HR 0.59; p=0.0034).
- Phase 2 PrTK05 trial data indicated systemic expansion and activation of multiple circulating cytotoxic T-cell populations.
- Biodistribution and shedding data from PrTK05 trial on track for Q4 2026 BLA submission to the FDA.
The big picture
Candel Therapeutics' findings provide mechanistic support for long-term clinical outcomes in prostate cancer, highlighting the potential of aglatimagene besadenovec to induce a coordinated immune response. The data strengthen the biological rationale for evaluating the therapy in other solid tumor indications where systemic disease control is critical. The upcoming BLA submission marks a significant milestone in the company's efforts to bring this multimodal immunotherapy to market.
What we're watching
- Regulatory Approval
- Whether the FDA will accept the BLA submission in Q4 2026 and the timeline for potential approval.
- Clinical Validation
- The pace at which additional data from the PrTK05 trial will be presented at scientific conferences and published in peer-reviewed journals.
- Market Expansion
- How the evidence of systemic immune activation will influence the evaluation of aglatimagene in metastatic solid tumor settings.